© 2020 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
London-The European Commission (EC) has approved Allergan Inc.'s bimatoprost ophthalmic solution 0.03% (Lumigan) as a first-line therapy to reduce IOP in chronic open-angle glaucoma and ocular hypertension.